Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 31, 2023 16:01 ET | Source: ObsEva SA

ObsEva Files Year End 2022 Financial Statements

ObsEva Files Year End 2022 Financial Statements Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 31, 2023 – ObsEva SA (SIX: OBSN / OTC Pink Market:...
March 21, 2023 08:00 ET | Source: ProPhase Labs, Inc.

ProPhase Labs to Host 2022 Year End Financial Results Conference Call on Tuesday, March 28, 2023 at 11:00 a.m. Eastern Time

GARDEN CITY, NY, March 21, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, will hold a conference call on...
March 05, 2021 01:00 ET | Source: ObsEva SA

ObsEva Announces Year End 2020 Financial Results and Business Update

-Yselty® for uterine fibroids: US New Drug Application filing planned in Q2:21; European marketing approval anticipated in Q4:21- -Yselty® for endometriosis: Readout from Phase 3 EDELWEISS 3...
March 05, 2020 04:43 ET | Source: ObsEva SA

ObsEva SA Link to Annual Report 2019

Geneva, Switzerland and Boston, MA – March 5, 2020 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s...
March 05, 2020 01:00 ET | Source: ObsEva SA

ObsEva Announces Year End 2019 Financial Results and Business Update

Primary endpoint achieved in 94% of women in linzagolix Phase 3 PRIMROSE 2 trial in uterine fibroids Linzagolix Phase 3 PRIMROSE 1 six-month primary endpoint results and PRIMROSE 2 twelve-month...
February 25, 2019 08:00 ET | Source: VBI Vaccines, Inc.

VBI Vaccines Provides Corporate Update, Outlook for 2019, and Year-End 2018 Financial Results

Top-line data from Hepatitis B (Sci-B-Vac®) Phase 3 PROTECT trial expected mid-year 2019Encouraging early immunogenicity data from GBM Phase 1/2a supports advancing into Part B of the studyLicense and...